艾迪注射液联合埃克替尼治疗非小细胞肺癌的临床研究

目的 研究艾迪注射液联合埃克替尼治疗非小细胞肺癌的效果。方法 选择2015年6月-2018年6月榆林市第一医院收治的84例非小细胞肺癌患者随机分为两组，每组42例。对照组采用盐酸埃克替尼片，观察组采用盐酸埃克替尼片联合艾迪注射液治疗，50 mL/次，1次/d。1个疗程为3周，均治疗3个疗程。比较两组的生活质量改善率、T细胞亚群水平和不良反应情况。结果 治疗后，观察组的有效率为69.05%，显著高于对照组的45.24%（P<0.05）。治疗后，观察组的生活质量改善率为61.90%，显著高于对照组的33.33%（P<0.05）。治疗后，观察组的CD8⁺、CD4⁺、CD3⁺和CD4⁺/CD8⁺水平均明显高于治疗前和对照组，差异均有统计学意义（P<0.05）；对照组治疗前后比较差异无统计学意义。观察组白细胞下降、恶心呕吐、血小板下降的发生率明显低于对照组（P<0.05），两组肝、肾功能异常率相比无明显的差异。结论 艾迪注射液联合埃克替尼对非小细胞肺癌的效果较佳，能改善其CD细胞亚群水平和生活质量，减轻不良反应。

Clinical study of Ektinib combined with Aidi Injection in treatment of nonsmall cell lung cancer

Objective To study the clinical effect of Aidi Injection combined with icotinib in treatment of non-small cell lung cancer. Methods Selected 84 cases of patients with non-small cell lung cancer from June 2015 to June 2018, divided into two groups randomly, and each group had 42 cases. The control group was treated with Icotinib Hydrochloride Tablets, 125 mg/time, three times daily. While the observation group was treated with Icotinib Hydrochloride Tablets combined with Aidi Injection, 50 mL/time, once daily. One course of treatment was 3 weeks, all of them were treated for 3 courses. The improvement rate of quality of life, the level of T cell subsets, and adverse reactions were compared between two groups. Results After treatment, the effective rate of the observation group was 69.05%, which was significantly higher than 69.05% in the control group (P<0.05). After treatment, the improvement rate of quality of life in the observation group was 61.90%, which was significantly higher than 33.33% in the control group (P<0.05). After treatment, the level of CD8⁺, CD4⁺, CD3⁺, and CD4⁺/CD8⁺ in the observation group after treatment was significantly higher than that before treatment and control group (P<0.05). There was no significant difference before and after treatment in the control group. The incidence of leukopenia, nausea, vomiting and thrombocytopenia in the observation group was significantly lower than control group (P<0.05). There was no significant difference in the abnormal rate of liver and kidney function between two groups. Conclusion Aidi Injection combined with Icotinib Hydrochloride Tablets has better effect on nonsmall cell lung cancer, can improve the level of T cell subsets and quality of life, and reduce adverse reactions.